Vertex Pharmaceuticals Inc. Stock Sheds 4.3%, Underperforms Peers

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of Vertex Pharmaceuticals Inc. slid 4.3% to $485.22 on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index remaining mostly unchanged at 7,805.45 and the Dow Jones Industrial Average falling 0.3% to 51,670.10.

This was the stock's second consecutive day of losses.

Vertex Pharmaceuticals Inc. closed 13.4% below its 52-week high of $560.25, which the company achieved on September 3rd.

The stock demonstrated a mixed performance when compared to some of its peers, as AbbVie Inc. fell 2.4% to $274.36, Krystal Biotech Inc. fell 3.3% to $321.16, and Arcturus Therapeutics Holdings Inc. fell 4.60% to $12.03.

Trading volume totaled 1.1 million, compared to the 50-day average of 1.1 million.

Data source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

October 13, 2026 16:34 ET (20:34 GMT)